Scotia Capital’s NanoViricides NNVC Stock Holding History

Scotia Capital’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-945	Closed	-$5K	–	764
2019 Q2	$5K	Hold	945	–	–	﹤0.01%	723
2019 Q1	$5K	Hold	945	–	–	﹤0.01%	696
2018 Q4	$4K	Sell	945 -24	-2%	-$154	﹤0.01%	654
2018 Q3	$7K	Hold	969	–	–	﹤0.01%	715
2018 Q2	$16K	Buy	969 +24	+3%	+$295	﹤0.01%	665
2018 Q1	$16K	Hold	945	–	–	﹤0.01%	698
2017 Q4	$17K	Hold	945	–	–	﹤0.01%	708
2017 Q3	$22K	Buy	945 +130	+16%	+$3.49K	﹤0.01%	693
2017 Q2	$22K	Hold	815	–	–	﹤0.01%	672
2017 Q1	$18K	Hold	815	–	–	﹤0.01%	722
2016 Q4	$17K	Hold	815	–	–	﹤0.01%	790
2016 Q3	$28K	Hold	815	–	–	﹤0.01%	768
2016 Q2	$26K	Buy	+815	New	+$29.7K	﹤0.01%	702

Other funds holding NNVC

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Scotia Capital's NNVC Position: Q3 2019 in Review

Scotia Capital sold out of NanoViricides (NNVC) in Q3 2019, closing a stake of 945 shares — an estimated $5K sold.

Scotia Capital first reported a position in NNVC in Q2 2016 and held it in 13 quarters. The position peaked at $28K in Q3 2016. 17 funds tracked by Wall St. Rank hold NNVC as of Q3 2019.

Scotia Capital reported no remaining NanoViricides position as of Q3 2019 after selling out during the quarter.
Scotia Capital sold 945 NanoViricides shares in Q3 2019, an estimated $5K.
Scotia Capital first reported a position in NanoViricides in Q2 2016 and held it in 13 quarters.
Scotia Capital's NanoViricides position peaked at $28K in Q3 2016.
17 funds tracked by Wall St. Rank held NanoViricides as of Q3 2019.

Based on Scotia Capital's 13F filing for Q3 2019, filed 14 Nov 2019.